Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1644
This examiner grants 60% of resolved cases
Nora Maureen Rooney is an examiner in Art Unit 1641 of Tech Center 1600. The examiner has 748 resolved cases and an allowance rate of 60.3 percent. This data reflects a consistent track record across a large volume of patent applications, providing a reliable baseline for applicants. The 60.3 percent allowance rate suggests a balanced examination environment where success is achievable through diligent prosecution and clear technical disclosure of the invention's merits.
The interview lift for this examiner is 23.6 percent. This positive figure indicates that interviews are an effective tool for applicants to increase their chances of allowance. Direct dialogue appears to be a helpful mechanism for resolving prosecution hurdles, as the 23.6 percent lift demonstrates a clear benefit to oral advocacy. Practitioners should leverage this by preparing thoroughly for interviews to address the examiner's specific concerns and negotiate claim language that satisfies both parties.
The median days to allowance is 1272. This timeframe provides applicants with an estimate of the total time required to reach a final decision on their patent applications under this examiner's review. The 1272-day median is an essential metric for managing the expectations of stakeholders and for planning the timing of related filings. It underscores the importance of a proactive prosecution strategy to navigate the multi-year process within Art Unit 1641.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18015684 | COMPREHENSIVE ANALYSIS OF ANTI-ALLERGEN ANTIBODIES USING PHAGE DISPLAY | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 17905520 | MULTISPECIFIC BINDING PROTEINS AND METHODS OF DEVELOPING THE SAME | Final Rejection | Eli Lilly and Company |
| 18016243 | TARGET-RECOGNITION OF ANTIGEN-MHC COMPLEX REPORTER (TRACER) PLATFORM | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18117752 | TRANSMUCOSAL AMPHIPHILE-PROTEIN CONJUGATE VACCINE | Final Rejection | Massachusetts Institute of Technology |
| 18952889 | NOVEL ANTI-PD-L1 ANTIBODIES | Non-Final OA | WUXI BIOLOGICS IRELAND LIMITED |
| 18669172 | Anti-CTLA-4 Antibodies and Uses Thereof | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18232238 | HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17797540 | METHODS FOR PRODUCING AND/OR ENRICHING RECOMBINANT ANTIGEN-BINDING MOLECULES | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 18267795 | BIFUNCTIONAL ANTI-PD1/IL-7 MOLECULES | Non-Final OA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
| 18219930 | NANOPARTICLE-MEDIATED IMMUNE CELL MANUFACTURE AND USE THEREOF | Non-Final OA | CHILDREN'S NATIONAL MEDICAL CENTER |
| 18025833 | ANTIBODY BINDING HUMAN IL-5R alpha AND USE THEREOF | Final Rejection | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18310649 | KSHV ONCOPROTEIN ANTIGENS AND EPITOPES FOR EXPANDING ANTIGEN-SPECIFIC T CELLS | Final Rejection | Fred Hutchinson Cancer Center |
| 18029954 | CLEC9A antibodies | Non-Final OA | The University of Queensland |
| 18550111 | DETECTION OF BIOMARKERS USEFUL IN DIAGNOSING CHRONIC ENTEROPATHIES IN CATS | Non-Final OA | VETICA LABS, INC. |
| 17282491 | METHODS AND SYSTEMS FOR CONTROLLING THE AGONISTIC PROPERTIES OF ANTIBODY VARIABLE DOMAINS BY LIGHT | Non-Final OA | UNIVERSITÉ D'AIX MARSEILLE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy